Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma

Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma

To evaluate the safety and efficacy of combining yttrium-90 radioembolization (Y90-RE) with immune checkpoint inhibitor therapy, consecutive advanced unresectable hepatocellular carcinoma (HCC) patients treated between 2016 and 2022 with atezolizumab/bevacizumab or nivolumab within three-months pre-...

Full description

Bibliographic Details
Main Authors: Alexander Villalobos, Howard Hussein Dabbous, Olivia Little, Olumide Babajide Gbolahan, Mehmet Akce, Meghan Allegra Lilly, Zachary Bercu, Nima Kokabi
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Current Oncology
Subjects:
Y90 radioembolization
SIRT
nivolumab
atezolizumab
bevacizumab
anti-PD-L1
Online Access:https://www.mdpi.com/1718-7729/30/12/734

Internet

https://www.mdpi.com/1718-7729/30/12/734

Similar Items